HB 388 requires state health plans to reimburse state employees and elected officials for costs associated with GLP-1 medications (used for conditions like diabetes or obesity). It adds these specific drugs to the list of covered expenses under existing reimbursement policies. The bill establishes a clear process for employees to seek reimbursement for these medications through their state health plan. This directly affects state workers who use GLP-1 drugs and ensures their costs are covered under state health benefits.
SB 227 would limit how much patients pay out-of-pocket for prescription insulin each month. It caps cost sharing at $35 per month for all insulin drugs covered under the bill. This directly affects people with diabetes who rely on insulin prescriptions. The law would require health plans and insurers to cover insulin costs above $35 at no additional charge to the patient.
SB 249 would authorize pharmacists to dispense ivermectin without a prescription by enacting section 4729.44 of Ohio's Revised Code. This change would allow patients to obtain ivermectin directly from pharmacies, bypassing the requirement for a physician's order. The bill establishes specific conditions for this dispensing process, including requirements for pharmacist verification. It directly affects pharmacies and patients seeking ivermectin for medical purposes without a prescription.
To amend sections 3902.50 and 3902.70; to amend, for the purpose of adopting a new section number as indicated in parentheses, section 3902.72 (3902.75); and to enact new section 3902.72 of the Revised Code to prohibit drug manufacturers from taking certain actions regarding reimbursements made to 340B covered entities.
HB 448 (Apply prescription drug rebates to cost-sharing requirements) requires health insurers and pharmacy benefit managers in Ohio to apply prescription drug rebates directly toward reducing the out-of-pocket costs patients pay for medications. This means savings from drug rebates - currently often retained by insurers - would lower patient copays, deductibles, or other cost-sharing amounts instead. The bill specifically targets how rebates are allocated under Ohio’s Revised Code, affecting insured patients who pay cost-sharing for prescription drugs. It does not change rebate amounts or drug pricing but alters how those rebates are used to benefit consumers. The policy change aims to make prescription medications more affordable for covered patients by redirecting savings.
To amend section 3959.01 and to enact sections 3957.01, 3957.02, 3957.03, 3957.04, 3957.05, 3957.06, 3957.07, 3957.08, 3957.09, 3957.10, 3957.11, 3957.12, 3957.13, 3957.14, 3957.15, 3957.16, 3957.17, and 3957.99 of the Revised Code to establish a stand-alone licensing process and new contractual requirements for pharmacy benefit managers.
To amend section 3902.50 and to enact sections 3902.75, 3902.76, and 3959.151 of the Revised Code to limit insurer accreditation requirements for pharmacies, to implement drug cost reporting requirements for pharmacy benefit managers, and to name this act the Community Pharmacy Protection Act.
To amend sections 3902.50 and 3902.70; to amend, for the purpose of adopting a new section number as indicated in parentheses, section 3902.72 (3902.75); and to enact new section 3902.72 of the Revised Code to prohibit drug manufacturers from taking certain actions regarding reimbursements made to 340B covered entities.
